Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have earned a consensus rating of “Buy” from the twenty-three brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $108.83.
A number of brokerages have recently commented on BMRN. Wedbush reissued an “outperform” rating and issued a $110.00 price target on shares of BioMarin Pharmaceutical in a report on Monday. Deutsche Bank set a $124.00 price target on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Friday, February 23rd. Leerink Swann cut their price objective on shares of BioMarin Pharmaceutical from $142.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, February 23rd. Credit Suisse Group upped their price objective on shares of BioMarin Pharmaceutical from $113.00 to $116.00 and gave the company an “outperform” rating in a research note on Friday, March 2nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $125.00 price objective (up previously from $119.00) on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd.
In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 10,000 shares of the stock in a transaction on Friday, December 29th. The shares were sold at an average price of $89.61, for a total transaction of $896,100.00. Following the completion of the sale, the chief executive officer now owns 226,494 shares of the company’s stock, valued at approximately $20,296,127.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Elaine J. Heron sold 800 shares of the stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $88.90, for a total transaction of $71,120.00. Following the sale, the director now directly owns 38,385 shares of the company’s stock, valued at approximately $3,412,426.50. The disclosure for this sale can be found here. Insiders have sold a total of 104,627 shares of company stock valued at $9,314,362 in the last three months. 1.85% of the stock is currently owned by corporate insiders.
Shares of BioMarin Pharmaceutical (BMRN) traded down $1.50 during trading hours on Friday, hitting $84.66. 190,193 shares of the stock were exchanged, compared to its average volume of 1,346,453. The company has a market cap of $15,130.00, a price-to-earnings ratio of -93.04 and a beta of 1.73. BioMarin Pharmaceutical has a 1 year low of $77.04 and a 1 year high of $100.51. The company has a quick ratio of 2.12, a current ratio of 2.70 and a debt-to-equity ratio of 0.29.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.06). The company had revenue of $358.31 million during the quarter, compared to the consensus estimate of $346.24 million. BioMarin Pharmaceutical had a negative return on equity of 3.18% and a negative net margin of 8.91%. research analysts forecast that BioMarin Pharmaceutical will post -0.67 earnings per share for the current fiscal year.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.